Dr. Marbán has served as chief executive officer and a board member since November 2013. Dr. Marbán co-founded Capricor, Inc., a wholly owned subsidiary of Capricor Therapeutics, Inc., and became its chief executive officer in 2010.
Capricor Therapeutics is a biotechnology company developing cell- and exosome-based therapeutics for rare diseases. Its lead product candidate, Deramiocel, is an allogeneic cardiac-derived cell therapy in late-stage clinical development.
Dr. Litvack joined the Capricor, Inc. board in 2012 and serves as chairman and a member of its Nominating and Corporate Governance Committee. He studied at McGill University and completed a cardiovascular fellowship at Cedars-Sinai Medical Center.
The company offers a multi-stage pipeline exploring allogeneic cardiosphere-derived cells (CDCs) and exosome science for therapeutic approaches to treat a range of serious diseases.
The company may collect contact and demographic information during registration and use it to send users information about the site or services and contact them online or offline.
